Table 1 Demographic and clinical characteristics of patients with viral pneumonia according to empiric antibacterial therapy

Age

55 (45–66)

57.5 (45–65)

56 (45–69)

Male

33 (49.3)

15 (53.6)

32 (40.5)

Caucasian

43 (64.2)

17 (60.7)

45 (57.0)

African American

20 (29.9)

7 (25)

30 (38.0)

Weight (kg)

81.3 (65.5–95.3)

74.3 (67.5–104.2)

73.5 (55.1–88.7)*

BMI

27.6 (22.6–35.1)

27.3 (22.7–33.8)

25.8 (20.1–32.0)*

Prior admit within 90 days

2 (3.0)

0 (0)

3 (3.8)

Chronic heart failure

12 (17.9)

6 (21.4)

12 (15.2)

Coronary artery disease

13 (19.4)

4 (14.3)

15 (19.0)

COPD

12 (17.9)

9 (32.1)

16 (20.3)

Diabetes mellitus

25 (37.3)

8 (28.6)

25 (31.6)

Chronic kidney disease

15 (22.4)

5 (17.9)

21 (26.6)

ESRD on hemodialysis

6 (9.0)

0 (0)

7 (8.9)

Cirrhosis

2 (3.0)

0 (0)

1 (1.3)

Human immunodeficiency virus

1 (1.5)

0 (0)

2 (2.5)

Active malignancy

31 (46.3)

11 (39.3)

26 (33.0)

Stem cell transplant

14 (20.9)

5 (17.9)

10 (12.7)

Solid organ transplant

9 (13.4)

2 (7.1)

9 (11.4)

 Lung

4 (6.0)

2 (7.1)

8 (10.1)

 Heart

2 (3.0)

0 (0)

1 (1.3)

 Kidney

3 (4.5)

0 (0)

0 (0)

Immunosuppressive therapy

1 (1.5)

3 (10.7)

8 (10.1)*

Immunocompromised

39 (58.2)

15 (53.6)

44 (55.7)

CCI

4 (3–6)

3 (1–5)

4 (2–6)

Intensive care unit admit

44 (65.7)

17 (60.7)

63 (79.7)

 Oncology^a

18 (26.9)

5 (17.9)

16 (20.3)

 Nononcology

26 (38.8)

12 (42.9)

47 (59.5)*

Mechanical ventilation

34 (50.7)

10 (35.7)

53 (67.1)**

 Days

5.9 (3.4–13.7)

3.7 (1.85–27.2)

7.0 (3.3–11.9)*

Central line placed

56 (83.6)

14 (50)

53 (67.1)*

Vasopressor support

14 (20.9)

4 (14.3)

35 (44.3)*^,**

 Days

3.55 (1.93–13.1)

2.2 (0.8–10.6)

6.3 (3.4–11.6)

APACHE II score

15 (11–20)

14 (8–17)

19 (14–23)*^,**